

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number
WO 03/020173 A1

(51) International Patent Classification⁷: **A61F 2/06**,
A61M 25/00

(21) International Application Number: PCT/AU02/01225

(22) International Filing Date:
4 September 2002 (04.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PR 7488 4 September 2001 (04.09.2001) AU

(71) Applicants and

(72) Inventors: **COCKS, Graeme** [AU/AU]; Unit 2, 14 Hilly Street, Mortlake, NSW 2137 (AU). **WHITE, Geoffrey, H.** [AU/AU]; 94 Louisa Road, Birchgrove, NSW 2041 (AU).

(74) Agent: **F B RICE & CO**; 605 Darling Street, Balmain, NSW 2041 (AU).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A STENT



(57) Abstract: A stent (10) which may be used in the treatment of stenosis and particularly ostial stenosis. The stent (10) includes a flange member (15) which engages the surrounding wall of an ostium and anchors the stent (10) in its target vessel. A delivery system for a stent (10) is also disclosed, the delivery system including a membrane (109) or a compression member to hold an intraluminal stent (101) in a first radially compressed state until said stent (101) is delivered to a target site.



WO 03/020173 A1

"A stent"

Field of the Invention

5 The present invention relates to a stent for use in occlusive disease and particularly occlusive disease in an area of vessel which branches into a second vessel.

Background of the Invention

10

 Occlusive diseases affecting the vasculature or other vessels are common. Such diseases include atherosclerosis which is characterised by a build up of plaque from cholesterol residues. The plaque build up subsequently thickens and hardens the vessel wall to create a stenosis. The resultant
15 narrowing of the vessel has adverse effects on blood flow through the vessel.

 Stenotic plaques may occur at any location along a vessel wall and in some cases may present at a junction between two vessels. This is commonly referred to as ostial stenosis or a narrowing of the opening of a vessel. In such
20 cases, the plaque or area of stenosis may severely compromise the flow of blood to the "downstream" vessel.

 Many vessels branch from a main vessel at approximately 90°. An example is the branching of the right and left renal arteries from the abdominal
25 aorta. Ostial stenosis may occur at the junction between the aorta and the renal artery and may predispose the patient to atheroembolisation of the visceral and peripheral vascular beds in addition to impairing blood flow to the kidney.

30 Current medical practices employ both invasive and non-invasive procedures to address stenosis including ostial stenosis. While the disease may be medically treated, in severe cases surgical intervention may be required. The latter includes both balloon angioplasty to break up the stenotic plaque and the delivery of an intraluminal stent to bridge the stenotic lesion.

35

While both procedures are commonly used, the incidence of re-stenosis in patients treated by balloon angioplasty is unacceptably high at an estimated 40% of cases. Bridging of the stenotic lesion with a stent significantly reduces the incidence of re-stenosis.

5

Conventional stents may be inserted percutaneously through a distal and connecting vessel to that in which the stent is to be used. For example, the device may be inserted through the femoral artery in a catheter, where the device is intended to be used in the treatment of a stenotic lesion. Upon
10 release of the device from the catheter it may expand to a desirable size, and may extend above and below the lesion thereby bridging that lesion.

The delivery of a stent to an ostial stenosis is a difficult procedure. In the case of stenosis at the opening or ostium of the renal arteries, in order to bridge
15 the stenosis, the stent is required to project around 1-2 mm into the aorta. As the majority of stents are a simple tubular mesh structure, they may shift from the desired position during the procedure. In such an event, the stent will either end up positioned too far into the renal artery or projecting too far into the aorta. Similar difficulties are experienced with the placement of a stent in other
20 regions of ostial stenosis in visceral vessels such as the mesenteric arteries and iliac arteries.

The present invention aims to provide a stent which overcomes the abovementioned problems of the prior art

25

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were
30 common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Summary of the Invention

35 Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a

stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

5 The present invention consists in an intraluminal stent comprising a tubular body extending from a proximal end to a distal end, said tubular body being capable of expanding or being expanded from a radially compressed state to a radially expanded state wherein, when at least in the radially expanded state, the tubular body includes at least a first flange member
10 positioned at or adjacent to the proximal end of the tubular body and extending outwardly from said tubular body.

 In one embodiment, the first flange member extends outwardly and away from the proximal end of the tubular body of the stent to give the tubular body a
15 trumpet-like appearance.

 The first flange member may be integral with the proximal end of the tubular body and may extend to an outer rim. The outer rim may form a lipped portion which may curve back in a general direction towards the distal end of
20 the tubular body. Alternatively, the first flange member may be formed as a separate member to the remainder of the tubular body wherein the first flange member is subsequently connected to the tubular body.

 Preferably, the lipped portion is integral with the first flange member such
25 that it forms a continuous curved structure extending initially outwardly and away from the proximal end of the tubular body before curving back in a general direction towards the distal end of the tubular body.

 The first flange member is typically made from the same material as the
30 remainder of the tubular body. Alternatively, the first flange member may be made from a different material from the material of the remainder of the stent.

 In another embodiment, the intraluminal stent includes a second flange member positioned at or adjacent the distal end of the tubular body.

The second flange member preferably extends outwardly and away from the distal end of the tubular body of the stent.

5 The second flange member may be integral with the distal end of the tubular body and may extend to an outer rim. The outer rim may form a lipped portion which may curve back in a general direction towards the proximal end of the tubular body.

10 Preferably, the lipped portion is integral with the second flange member such that it forms a continuous curved structure extending initially outwardly and away from the distal end of the tubular body before curving back in a general direction towards the proximal end of the tubular body.

15 The second flange member is typically made from the same material as the remainder of the tubular body. Alternatively, the second flange member may be made from a different material than the material of the remainder of the stent. Additionally, the second flange member may be formed as a separate member to the remainder of the tubular body and subsequently connected to the tubular body.

20

Preferably, the first and second flange members are made during the manufacture of the intraluminal stent of the invention. The elected method for achieving such flanged members will primarily depend on the material selected to comprise the stent and the flange member although it is envisaged that both
25 the tubular body of the stent and the flange member would be formed by laser cutting/etching of a suitable material such as stainless steel or Nitinol™. In this regard, the tubular body of the present invention may be made by providing a cylinder of the material to be used and laser cutting said material in the cylindrical form. The laser cutting typically results in the formation of a series of
30 cells along the length of the circumference of the cylinder. The cells may be of the same size along the length of the cylinder or may vary in size along the length. This will be discussed in greater detail below.

In the embodiment wherein the tubular body is made from a shape
35 memory material such as Nitinol™, the cylinder of material is laser cut to form the series of cells. The cylinder is then taken to the desired temperature to

allow the material to achieve a "memory" of a certain expanded configuration. At this temperature, a template is used to push the area of the cylinder which is to become the at least first flange member outwardly relative to the remainder of the cylindrical tubular body. The material of the cylinder is then cooled from
5 this temperature such that the material resumes a compressed substantially cylindrical shape without the flanged end. When the final stent made from this cylinder is inserted into a vessel of a patient, it is preferable that when the material is exposed to the body temperature of the patient it takes on its "memorised" shape, that is, a tubular body having at least a first flange member
10 positioned at or adjacent to a proximal end of the tubular body.

In an embodiment wherein the material of the stent is not a shape memory material, it is envisaged that a pre-formed tubular body having at least a first flange member positioned at least adjacent the proximal end of the
15 tubular body is formed. The pre-formed tubular body may then be laser cut into a desired series of cells.

In a preferred embodiment, the cells of the tubular body may be of varying size and configuration along the length of the tubular body. For
20 example, it is envisaged that the at least first flange member is made from a series of cells which are larger and/or more elongate than the remainder of the cells of the tubular body. Furthermore, it is preferred that the cells of the flange member in addition to being more elongate, are formed at an angle to the remainder of the cells of the tubular body.

25 The tubular body may further include a transition region adjacent the at least first flange member. The transition region is preferably made up of a series of cells which have a small pore size relative to the cells of the at least first flange member and the remainder of the tubular body. In this embodiment,
30 the transition region provides an area of relatively high expansile strength. In cases where the stent is used in ostial stenosis, which will be discussed further below, the transition region has the advantage of "pinning back" an area of stenosis around the ostium of a vessel.

35 The at least first flange member may comprise two cells located on opposing walls of the tubular body. In this embodiment the two cells form strut

members which have the effect of anchoring the stent in a vessel, particularly when the stent is used to treat ostial stenosis as further discussed below. It should be noted, however, that the present invention encompasses all possible cell patterns in the wall of the tubular body and including the at least first flange
5 member.

While the tubular body of the stent may be formed of a thin biocompatible material such as NitinolTM or stainless steel, other alloys such as tantalum or Elgiloy are also envisaged. The tubular body may be bare or may
10 be coated with a material having an elastic property such that the coating material is capable of covering the tubular body in both the radially compressed state and the radially expanded state.

In a preferred embodiment of the invention, the tubular body may be
15 formed from other suitable biocompatible materials, selected, for best results, on the basis of the material's capacity to withstand the compressive forces of the stenotic lesion and maintain patency of the vessel throughout the life of the stent.

20 Preferably, the intraluminal stent of the present invention is used in the treatment of ostial stenosis although it is equally envisaged that it could be used in any other form of stenosis. In ostial stenosis, the plaque or stenotic region is formed at the junction between a pre-branching vessel and a post-branching vessel. The stenotic plaque surrounds the ostium of the post-
25 branching vessel which has the effect of narrowing the ostium of the post-branching vessel.

While the stent of the present invention may be used to treat ostial stenosis of the visceral arteries such as the renal and mesenteric arteries, the
30 iliac artery, and the sub-clavian artery, it may also be used to treat stenotic lesions in the peripheral vasculature and the coronary circulation. However, the application of the invention for use in the treatment of stenotic disease is not to be understood as limited to the vascular system only. The stent may be used to treat stenotic lesions in other vessels including, for example, those
35 comprising the hepato-biliary and genito-urinary tracts

In the treatment of ostial stenosis, the first flange member is preferably positioned within the pre-branching vessel. In this embodiment, the first flange member typically engages at least a portion of the wall of the pre-branching vessel which surrounds the ostium of the post-branching vessel. The remainder of the tubular body of the stent can extend into the post-branching vessel. Accordingly, the at least first flange member has the effect of anchoring the stent within the post-branching vessel thereby preventing longitudinal movement of the stent into the post-branching vessel. If such movement occurs, the stent moves away from the stenotic lesion and thereby does not have the desired function of bridging the stenotic lesion.

In the embodiment of the invention which includes a second flange member positioned adjacent the distal end of the tubular body, when the stent is used in the treatment of ostial stenosis, the second flange member is positioned within the post-branching vessel and preferably engages the wall of said post-branching vessel. This further secures the intraluminal stent within the post-branching vessel thereby preventing longitudinal movement of the stent in the vessel.

The tubular body of the stent may further include at least one engagement member. The at least one engagement member may be connected to or integral with a wall of the tubular body at a position located intermediate the proximal end and the distal end of the tubular body.

Preferably, the tubular body includes more than one engagement member which may comprise a number of spurs or other such members which extend outwardly from the tubular body of the stent. When the stent is in use, the spurs extend towards and engage with the wall of the vessel in which the stent is positioned. This has the function of further securing the stent within the vessel.

In a further embodiment, rather than a spur, the at least one engagement member may comprise a ridge or like area or a series of ridges of increased cross sectional diameter than those portions of the tubular body immediately proximal and distal each ridge. When the stent is in use, the ridge or like area

or series of ridges extend(s) towards and engage(s) with the vessel wall thereby assisting in the securing of the stent in the vessel wall.

The at least one engagement member may be made from the same
5 material as the remainder of the tubular body or may be made from a different material. It is envisaged that the at least one engagement member may be made from a shape memory material such as Nitinol™.

The connection between the at least one engagement member and the
10 tubular body of the stent may be such that allows the at least one engagement member to occupy a first angular relationship with an adjacent part of the tubular body when the tubular body is in its compressed state wherein the at least one engagement member occupies a second and different angular relationship with the tubular body when the tubular body is in its expanded
15 state.

The at least one engagement member is preferably created during the manufacture of the stent of the invention. Where the tubular body and the at least one engagement member are made from a shape memory material such
20 as Nitinol™, a cylinder of Nitinol™ is taken to a desired temperature to allow the material to achieve a "memory" of a certain configuration. If the at least one engagement member is a ridge as described above, when the cylinder is taken to this temperature, a template is used to push the area of the cylinder which is to become the at least one engagement member outwardly from the
25 remainder of the cylindrical tubular body. The material of the cylinder is then cooled from this temperature such that the material resumes its compressed and substantially cylindrical shape without the ridge. When the final stent made from this cylinder is inserted into a vessel of a patient, it is preferable that when the material is exposed to the body temperature of the patient it takes on its
30 "memorised" shape, that is, a tubular body having at least one engagement member extending outwardly therefrom.

Alternatively, wherein the tubular body is made up of a series of cells, the at least one engagement member may comprise a number of cells linked to
35 one another wherein said cells extend around the circumference of the tubular body. Each cell preferably has an area of weakness which upon expansion of

the tubular body from the compressed state to the expanded state buckles thereby forming a rib or a series of ribs for engagement with the vessel. This embodiment may be useful wherein the tubular body is made from a material such as stainless steel.

5

In a further embodiment, the at least one engagement member may be made up of a series of connector members which connect the cells on either side of the at least one engagement member. In this regard, the connector members may be relatively straight members and may connect every second
10 cell on either side of the at least one engagement member. In this embodiment, when the tubular body moves from the radially compressed state to the radially expanded state, the free ends of every second cell which are not connected by the connector members turn outwardly away from the tubular body and engage with the vessel wall.

15

The tubular body may be coated with materials to promote adhesion of cells or cell growth to assist in securing the device tubular body in place in the post-branching vessel. It is further envisaged that the tubular body may be coated with any of a number of pharmaceutical agents.

20

In a preferred embodiment, during use of the intraluminal stent of the present invention, the tubular body is initially in the radially compressed state to enable delivery of the stent through an introducer catheter. Upon deployment of the stent into a selected vessel, the tubular body may be caused to expand,
25 or may be allowed to self-expand into the expanded state.

There are at least three preferred mechanisms whereby the tubular body may change from the radially compressed state to the radially expanded state. For instance, the tubular body may be expanded by the force of an inflating
30 balloon within the tubular body or by some other mechanically applied force.

Alternatively, the tubular body may be made from a shape memory material as mentioned above wherein the patient's body temperature causes the temperature of the tubular body to move towards the same temperature,
35 thereby enabling the tubular body to self-expand and take on its "memorised" shape.

In a further embodiment, the tubular body may self expand following deployment of the tubular body from an introducer catheter used to introduce the stent invention into the body of a patient. This particular embodiment relies upon spring expansion of the material of the tubular body following release of the compressive force of the introducer catheter.

The first and/or the second flange member may expand by a different mechanism to the mechanism of expansion of the remainder of the tubular body. For example the flange member(s) may be made from a shape memory material such as Nitinol™ whereas the remainder of the tubular body may be made from a spring expandable material such as stainless steel. In this case, upon deployment of the stent within a vessel, the flange members would take on their "memorised" shape and the remainder of the body would spring into shape having been compressed in the delivery catheter. Various combination of the above mechanisms are envisaged.

In a second aspect, the invention relates to a method of positioning an intraluminal stent according to the first aspect of the invention in a vessel of a patient, the method comprising the steps of:

- (i) introducing a catheter or other delivery device into a vein, artery or other vessel in the body of a patient when the tubular body of the intraluminal stent is in the radially compressed state;
- (ii) causing the intraluminal stent to be carried through the catheter or other delivery device to a target site of stenosis at a bifurcation between a first pre-branching vessel and a second post-branching vessel;
- (iii) causing or allowing the tubular body of the intraluminal stent to expand such that the at least first flange member is positioned at least partially within the pre-branching vessel and the remainder of the tubular body of the stent extends into the post-branching vessel; and
- (iv) withdrawing the catheter or other delivery device along with any other apparatus used to introduce the intraluminal device into the vessel from the body of the patient.

The length and radially expanded diameter of the tubular body may be determined by the individual circumstances of the application to which the

intraluminal device is to be put. Typically, the bifurcating vessel is assessed by X-ray or other similar examination and a suitably dimensioned device selected for that application.

- 5 The intraluminal stent may have radio-opaque markers incorporated into the tubular body to enable a surgeon to view the position of the stent within the vessels.

10 In a third aspect, the present invention provides a delivery system for the delivery of the intraluminal stent of the first aspect to a target vessel, said delivery system comprising an introducer catheter having an elongate tubular body to allow the passage therethrough of a placement catheter, said placement catheter having an elongate body which extends from a proximal end to a distal end and which carries the stent of the first aspect of the
15 invention at a position intermediate said proximal end and said distal end, the delivery system further comprising a membrane which engages a portion of the tubular body of the intraluminal stent not comprising the at least first flange member and wherein said membrane acts to maintain said portion of the tubular body in its radially compressed state.

20

 In a fourth aspect, the present invention provides a method of delivering the intraluminal stent of the first aspect using the delivery system of the third aspect, said method comprising the steps of:

- 25 (i) introducing the introducer catheter into a vein, artery or other vessel in the body of a patient wherein the tubular body of the intraluminal stent is in the radially compressed state;

- (ii) causing the intraluminal stent, the placement catheter and the membrane to be carried through the introducer catheter to a target site of stenosis at a bifurcation between a first pre-branching vessel and a second
30 post-branching vessel;

- (iii) introducing the distal end of the placement catheter into the post-branching vessel from the pre-branching vessel until substantially only the at least first flange member is still positioned within the pre-branching vessel;

- 35 (iv) withdrawing the introducer catheter to expose the at least first flange member of the intraluminal stent;

(v) causing or allowing the at least first flange member to move from its radially compressed state to its radially expanded state such that it is caused to abut with at least a portion of the wall of the pre-branching vessel which surrounds the opening of the post-branching vessel;

5 (vi) advancing the placement catheter and the membrane further into the post-branching vessel such that the compression on the portion of the tubular body substantially surrounded by the membrane, by said membrane is released, allowing said portion of the tubular body to move from its radially compressed state to its radially expanded state and into abutment with at least
10 a portion of the wall of the post-branching vessel; and

(vii) withdrawing the placement catheter together with the membrane through the expanded tubular body.

In a fifth aspect the present invention provides a delivery system for the
15 delivery of an intraluminal stent to a target vessel, said delivery system comprising an introducer catheter having an elongate tubular body to allow the passage therethrough of a placement catheter, said placement catheter having an elongate body which extends from a proximal end to a distal end and which carries the intraluminal stent at a position intermediate said proximal end and
20 said distal end; the delivery system further including a membrane which engages at least a portion of the intraluminal stent such that said portion of the stent is prevented from moving from a first radially compressed state to a second radially expanded state.

25 In this fifth aspect, the stent can have the features of the stent according to the first aspect of the invention defined herein.

Preferably, the intraluminal stent is made from a shape memory material such as NitinolTM. In this embodiment, where the first flange member is present
30 and when the introducer catheter is withdrawn to expose the at least first flange member of the intraluminal stent, said first flange member is exposed to the body temperature of the patient whereupon it moves to its "memorised" position, that is, flaring outwardly from the remainder of the tubular body of the stent. In the treatment of ostial stenosis, this forms the anchor for the stent as
35 the flange member engages with the wall of the pre-branching vessel around the ostium of the post-branching vessel.

To ensure that the stent is appropriately positioned before the introducer catheter is withdrawn, the at least first flange member may have radio-opaque markers incorporated in its structure. Accordingly, in this embodiment, the surgeon would be able to determine the exact positioning of the at least first flange member within a vessel(s) of the patient. Not until the at least first flange member was positioned within the pre-branching vessel at an area adjacent the opening of the post-branching vessel and the remainder of the tubular body extending into the post-branching vessel would the introducer catheter be withdrawn.

As discussed above, the remainder of the tubular body of the stent which is positioned within the post-branching vessel is typically engaged by the membrane. In this regard, the membrane may extend around the circumference of the tubular body.

The membrane is preferably made from a suitably strong material to act as a compressive force upon the tubular body thereby preventing the tubular body from moving into the radially expanded state.

The membrane may be made of a biodegradable material and could therefore be left within the body of the patient although preferably, the membrane is also withdrawn with the placement catheter. Whichever arrangement is chosen, the effect is to release the pressure exerted on the tubular body such that it can move to its radially expanded state.

In the case of use of the stent in the treatment of ostial stenosis, the membrane preferably engages with all of the tubular body of the stent apart from the at least first flange member. Accordingly, when the introducer catheter is withdrawn, the at least first flange member is free to move from its radially compressed state to its radially expanded state. In this embodiment, it is envisaged that the membrane around the at least one portion of the tubular body may be broken to enable the at least one portion of the tubular body to move from its radially compressed state to its radially expanded state.

In one embodiment, the placement catheter may include a balloon member positioned at least partially internal the tubular body of the intraluminal stent. Upon inflation of the balloon member, the intraluminal stent is forced radially outwardly which has the effect of breaking the membrane. With the
5 membrane broken, the at least one portion of the tubular body is free to move into its radially expanded state. It is further envisaged that the membrane may include a frangible region which breaks upon the exertion of pressure caused by the inflation of the balloon member.

10 It is also further envisaged that the membrane may not break but rather the membrane is caused to radially expand with the radial expansion of the tubular body of the intraluminal stent. Such radial expansion may result from the force exerted by the inflation of the balloon member.

15 As discussed above, the membrane may be biodegradable in which case, upon placement of the tubular body in a target vessel, the membrane may degrade thereby allowing the tubular body to move to its radially expanded state.

20 The membrane can deliver any of a number of pharmaceutical agents to a target vessel. In this embodiment, the membrane may be coated with such agents. Furthermore, the membrane may comprise a number of layers carrying different pharmaceutical agents. Each layer may be biodegradable to expose another layer.

25

In a sixth aspect, the present invention provides a delivery system for the delivery of an intraluminal stent to a target vessel, said intraluminal stent being movable from a first radially compressed state to a second radially expanded state at a target site within the vessel, said delivery system comprising a
30 catheter which in turn comprises an elongate body which extends from a proximal end to a distal end wherein the elongate body extends through an internal lumen of the intraluminal stent such that said intraluminal stent substantially surrounds a portion of the catheter; the delivery system further comprising at least one compression member which holds the intraluminal stent
35 in its first radially compressed state and a release member which causes

release of the compression member and allows the intraluminal stent to move to its second radially expanded state.

It is preferred that the delivery system is used to deliver a self expanding
5 intraluminal stent to a target site.

In one embodiment, the compression member of the sixth aspect forms a membrane around the intraluminal stent. In this regard, the membrane is made from a suitably strong yet flexible material to compress the intraluminal stent
10 and prevent said stent moving from its first radially compressed state to its second radially expanded state.

In a further embodiment, it is envisaged that the compression member includes a tie member or a series of tie members which hold the intraluminal
15 stent around the catheter and prevent the intraluminal stent moving from its first compressed state to its second expanded state. For example, the tie member(s) may be sutures which have a pre-determined breaking strength. The sutures may be bonded to the intraluminal stent such that they do not form free particles during and after the deployment of said stent.

20

Alternatively, the compression member may comprise one or more of a collar, ring or spiral wrap or combinations thereof around the intraluminal stent.

The advantage of the delivery system of the sixth aspect is that the self
25 expanding intraluminal stent may be delivered to a target site without the requirement of a bulky introducer catheter to hold the intraluminal stent in its first radially compressed state. In this regard, the compression member of the delivery system holds the intraluminal stent in its radially compressed state until the stent is advanced on the catheter to the target site.

30

When the intraluminal stent reaches the target site, the release member may be activated to release the compressive force of the compression member on the intraluminal stent. In this regard, the release member may comprise a balloon member positioned along the length of the elongate body of the
35 catheter. The balloon member may form the portion of the elongate body of the catheter which is substantially surrounded by the intraluminal stent. The

balloon member may move from a deflated state during delivery of the catheter to a target site, to an inflated state at said target site. Movement of the balloon member to the inflated state may release the compressive force of the compression member.

5

Particularly, where the compression member is a membrane which surrounds the intraluminal stent, it is preferred that said membrane includes at least one frangible region such that when the balloon member moves from its deflated to inflated state, the frangible region(s) is broken and the intraluminal
10 stent allowed to move to its second radially expanded state. In this regard, in a preferred embodiment wherein the intraluminal stent is a self expanding stent, breaking the compression member at the frangible region(s) allows said stent to spring to its second radially expanded state, that is, the balloon member is typically inflated only a sufficient degree to break the engagement between
15 compression member and stent and need not be inflated further to cause the intraluminal stent to move from its first radially compressed state to its second radially expanded state. In one embodiment, said frangible region may comprise one or more perforations, such as a line of perforations, in the body of the membrane.

20

In the embodiment wherein the compression member comprises a number of sutures, as mentioned above, the sutures holding the intraluminal stent to the catheter have a predetermined breaking strength. Accordingly, when the balloon member moves from its deflated state to its inflated state, the
25 sutures break thereby allowing the intraluminal stent to move to its second radially expanded state.

Similarly, in further embodiments, the movement of the balloon member from its deflated to its inflated state may cause said one or more of the collar,
30 ring or spiral wrap to release their compressive force.

In another embodiment, where the compression member forms a membrane around the intraluminal stent, it is envisaged that said membrane has a perforation along at least a portion of its length. The release member in
35 this embodiment may be a pull suture which is aligned with and/or threaded through the perforation of the membrane. The pull suture typically extends to a

location outside the body or is connected to an actuator member located outside the body such that when the intraluminal stent is in position at a target site, the pull suture is drawn in a direction towards the proximal end of the intraluminal stent such that the perforation is broken and the compressive force
5 of the membrane released from the intraluminal stent which may then move to its radially expanded state.

In a further embodiment of this aspect, the compression member is an expandable membrane. The membrane can be sealed around the stent. In
10 this aspect, the release member comprises a fluid that can be delivered to the sealed membrane and so expand the membrane.

In one embodiment, the fluid can be delivered into the sealed membrane by the catheter through apertures therein.
15

In a preferred embodiment, the membrane breaks into one or more portions on undergoing a predetermined degree of expansion. Said one or more portions of the membrane can be connected to the catheter and are withdrawable from the target vessel on withdrawal of the catheter therefrom.
20

In a further embodiment, the membrane can contain or include one or more pharmaceutical agents. In another embodiment, one or more pharmaceutical agents can be delivered with the fluid from the catheter and into the pocket formed by the sealed membrane.
25

In a further embodiment, the stent can be a self-expanding stent that expands on expansion of the membrane. In another embodiment, the stent is a passive stent that requires expansion by a secondary mechanism, such as a balloon catheter.
30

Brief Description of the Drawings

Figure 1a is a cut-away view of anatomical structures of the abdomen of a subject.
35

Figure 1b is a magnified view of part of the structure depicted in Figure 1a.

Figure 2 is a perspective view of one embodiment of the intraluminal
5 stent of the invention.

Figure 3a is a view of the cell structure of the intraluminal stent depicted in Figure 2 when the stent is in an expanded state.

10 Figure 3b is a view of the cell structure of the intraluminal stent depicted in Figure 2 when the stent is in a compressed state.

Figure 4 is a perspective view of another embodiment of the intraluminal stent of the invention.
15

Figure 5a is a view of the cell structure of the intraluminal stent depicted in Figure 4 when the stent is in an expanded state.

Figure 5b is a view of the cell structure of the intraluminal stent depicted
20 in Figure 4 when the stent is in a compressed state.

Figure 6 is a perspective view of a further embodiment of the intraluminal stent of the invention.

25 Figure 7a is a view of the cell structure of the intraluminal stent depicted in Figure 6 when the stent is in an expanded state.

Figure 7b is a view of the cell structure of the intraluminal stent depicted in Figure 6 when the stent is in a compressed state.
30

Figure 8 is a side elevational schematic view of an embodiment of the invention.

Figure 9 is a side elevational schematic view of a further embodiment of
35 the present invention.

Figure 10 is a cross-sectional view of a further embodiment of the present invention.

Figure 11 is a schematic view of a delivery catheter according to the
5 present invention.

Figures 12a to 12d depict placement of the intraluminal stent according to the present invention in a vessel using the delivery catheter shown in Figure 11.

10

Figures 13a, 13b and 13c are cross-sectional views of further embodiments of the delivery catheter shown in Figure 11.

Figures 14a, 14b and 14c are views of further embodiments of the
15 present invention.

Figure 14d shows the cells structure of the embodiment of the invention depicted in Figure 14b.

Figures 15a and 15b show schematic views of a delivery system of
20 further aspect of the invention.

Figure 15c is a cross-sectional view showing the intraluminal stent and compression member of the delivery system depicted in Figure 15b.

25

Figure 16 is a schematic view of a further embodiment of the delivery system of the invention.

Figs. 17a and 17b are schematic views of a further embodiment of a
30 delivery system according to the present invention.

Figs. 18a and 18b are schematic views of a still further embodiment of a delivery system according to the present invention.

35

Preferred Mode of Carrying out the Invention

The intraluminal stent of the present invention is generally depicted as 10 in the accompanying drawings.

5

Preferably, the intraluminal stent of the present invention is used in the treatment of ostial stenosis although it is equally envisaged that it could be used in the treatment of any other form of stenosis. In ostial stenosis, the plaque or stenotic region 9 is formed at the junction between a pre-branching vessel 21 such as the aorta and a post-branching vessel 20 such as the renal artery which has the effect of narrowing the opening (ostium) of the post-branching vessel 20.

The intraluminal stent 10 comprises a tubular body 11 extending from a proximal end 12 to a distal end 13. The tubular body 11 is capable of expanding or being expanded from a radially compressed state (as depicted in Figures 3b, 5b and 7b) to a radially expanded state (as depicted in Figures 3a, 5a and 7a). When in the radially expanded state, the tubular body 11 includes a first flange member 15 positioned adjacent the proximal end 12 of the tubular body 11, with the first flange member 15 having a greater diameter than the diameter of the remainder of the tubular body 11.

The first flange member 15 extends outwardly and away from the proximal end 12 of the tubular body 11 giving the stent a trumpet-like shape as depicted in Figure 2.

The first flange member 15 is shown as forming a continuous, integral structure with the tubular body 11 and is typically made from the same material as the remainder of the tubular body 11.

30

During use of the intraluminal stent 10 (in the present case, the term "use" refers to the treatment of ostial stenosis), the tubular body 11 is initially in the radially compressed state to enable delivery of the stent 10 through an introducer catheter. Upon deployment of the stent 10 into a selected vessel, the tubular body may be caused to expand, or may be allowed to self-expand into the expanded state. The first flange member 15 is positioned at least

35

partially within pre-branching vessel 21 and the remainder of the tubular body of the stent extends into the post-branching vessel 20.

In use, the first flange member 15 is positioned in the pre-branching vessel 21, such as, for example, the aorta. The first flange member 15 typically engages at least a portion of the pre-branching vessel wall surrounding the ostium of the post-branching vessel 20 with the remainder of the tubular body 11 extending into the post-branching vessel 20. Accordingly, the first flange member 15 has the effect of anchoring the stent 10 within the post-branching vessel 20 thereby preventing longitudinal movement of the stent into the post-branching vessel 20.

While the tubular body 11 of the stent may be formed of a thin biocompatible material such as NitinolTM or stainless steel, other alloys such as tantalum or Elgiloy may be used. In the examples depicted, the stent is made from NitinolTM.

As depicted in Figures 3a, 3b, 5a, 5b and 7a, 7b, a cylinder of NitinolTM is laser cut to form a series of cells 22. The cylinder is then taken to the desired temperature to allow the material to achieve a "memory" of a certain configuration. At this temperature, a template is used to push the area of the cylinder 23 which is to become the first flange member 15 outwardly from the remainder of the cylinder. The material of the cylinder is then cooled from this temperature such that the material resumes its cylindrical shape without the flange member. When the final stent 10 made from this cylinder is inserted into a vessel of a patient, the material takes on its "memorised" shape, that is, a tubular body having a first flange member positioned at least adjacent the proximal end 12 of the tubular body 11.

In an embodiment wherein the material of the stent is not a shape memory material, it is envisaged that a pre-formed tubular body having at least a first flange member positioned at least adjacent the proximal end of the tubular body is formed. The pre-formed tubular body may then be laser cut into a desired series of cells.

As depicted in the figures, the cells 22 of the tubular body 11 may be of varying size or configurations along the length of the tubular body 11. In each of the figures, the first flange member 15 is made up of a series of elongate cells 23 which are angled from the remainder of the cells of the tubular body.

5 This region is generally depicted as (1) in the drawings. The region adjacent the first flange member 15 is depicted as (2). As can be seen, the cells of this region are generally of a large "bat-wing" shape which confer the desired flexibility while at the same time a certain degree of rigidity to the stent 10. In Figure 3a, region (2) extends from a region adjacent the first flange member 15

10 along the remainder of the length of the tubular body 11. In Figure 5a, region (2) is interrupted by region (x) which comprises a ring of cells 25 around the tubular body 11, wherein each cell is formed from a straight link 26 with a central hole 27. In one embodiment, wherein the material of the stent is not a necessarily a shape memory material, when the stent 10 is moved from a

15 compressed state to an expanded state, the cells on either side of region (x) are forced closer together thereby causing the straight links 26 to buckle outwardly of the tubular body 11 at a fold adjacent the central hole 27. This creates a ridge 31 on the tubular body 11 which is depicted in Figure 4 and will be discussed in further detail below.

20

Where the tubular body 11 is made from a shape memory material such as NitinolTM, a cylinder of NitinolTM is taken to a desired temperature to allow the material to achieve a "memory" of a certain configuration. If a ridge 31 as depicted in Figure 4 is to be formed, when the cylinder is taken to this

25 temperature, a template is used to push the area of the cylinder which is to become the ridge 31 outwardly from the remainder of the cylindrical tubular body. The material of the cylinder is then cooled from this temperature such that the material resumes its cylindrical shape without the ridge 31. When the final stent 10 made from this cylinder is inserted into a vessel of a patient, it is

30 preferable that when the material is exposed to the body temperature of the patient it takes on its "memorised" shape, that is, a tubular body 11 having a ridge 31 as depicted in Figure 4.

In a further embodiment of the invention as depicted in Figures 6, 7a and

35 7b, the stent 10 has a first flange member 15 and a second flange member 28. In this embodiment, the cells 23 of the first flange member 15 are of an

elongate shape and make up region (1). Region (2) of this embodiment comprises a series of "bat-wing" cells 22 which extend into from region (1) to region (3). Region (3) comprises the second flange member 28 and is made of a series of relatively large diagonal-shaped cells. Where the tubular body 11 is made from a shape memory material such as Nitinol™, the second flange member 28 may be formed in the same manner as described above for the first flange member 15.

In another embodiment of the invention as depicted in Figure 8, the tubular body is made up of regions (1), (2) and (3) wherein region (1) comprises the first flange member 15. Region (2) is made up of a series of cells 22 having a smaller, tighter pore size than the cells 22 of regions (1) and (3). This provides a region of relatively high expansile strength which acts to exert a force on a surrounding stenotic region when the stent is in use.

In one embodiment as depicted in Figure 9, the first flange member 15 comprises two cells 22 located on opposing walls of the proximal end 12 of the tubular body 11. In this embodiment, the two cells 22 form struts to engage the area surrounding the ostium of a post-branching vessel 20.

In a particularly preferred embodiment of the invention as depicted in Figure 10, the first flange member 15 in addition to extending outwardly and away from the proximal end 12 of the tubular body 11, doubles back on itself in a direction generally towards the distal end 13 of the tubular body 11. The first flange member 15 in this embodiment therefore forms a lipped structure which provides a good anchorage of the stent 10 when it is in use. Particularly, the lipped portion engages a region of the pre-branching vessel 21 around the ostium of the post branching vessel 20 thereby preventing movement of the stent 10 into the post-branching vessel 20 such that the stent does not bridge an area of stenosis around the ostium of the post-branching vessel.

As depicted in Figure 4, the tubular body 11 also includes an engagement member 30. The engagement member 30 is connected to or integral with a wall of the tubular body 11 at a position located intermediate the proximal end 12 and the distal end 13 of the tubular body 11.

The engagement member 30 depicted in Figure 4 is ridge 31. When the stent 10 is in use, the ridge 31 extends towards and engages with the post-branching vessel 20 wall thereby securing the stent in the post-branching vessel 20.

5

In a further embodiment depicted in Figures 14a-14d, the engagement member 30 may be made up of a series of connector members 51 which connect the cells on either side of the at least one engagement member 30. In this regard, the connector members 51 may be relatively straight members and
10 may connect every second cell on either side of the at least one engagement member. In this embodiment, when the tubular body moves from the radially compressed state to the radially expanded state, the free ends 51 of every second cell which are not connected by the connector members 50 turn outwardly away from the tubular body and are engageable with the vessel wall.

15

As mentioned above, the stent 10 of the present invention is used in the treatment of ostial stenosis including ostial stenosis of the visceral arteries such as the renal and mesenteric arteries, the iliac artery and the sub-clavian artery. Further, in addition to the treatment of stenotic lesions in the peripheral
20 vasculature, the stent 10 may be used in the treatment of vessels comprising the coronary circulation.

Figure 11 shows a delivery catheter 40 for the delivery of the intraluminal stent 10. The delivery catheter 40 includes an introducer catheter 41 having an
25 elongate tubular body to allow the passage therethrough of a placement catheter 42. The placement catheter 42 has an elongate body extending from a proximal end 43 to a distal end 44, the placement catheter carrying the stent 10 having body 11 at a position intermediate its proximal end 43 and its distal end 44. The delivery catheter 40 further includes a membrane 45 positioned
30 around the placement catheter 42 and connected to distal end 44 wherein the membrane 45 is positioned such that it does not surround the first flange member 15 of the intraluminal stent 10 and wherein the membrane 45 acts to compress the remainder of the tubular body and prevent it from moving to the radially expanded state.

35

When the intraluminal stent 10 is to be used to bridge an ostial stenosis, it is introduced as follows:

Step 1: the introducer catheter 41 is introduced by way of a vein, artery
5 or other vessel into the pre-branching vessel 21 of a patient. It should be noted that the tubular body of the intraluminal stent is in its radially compressed state;

Step 2: the distal end 44 of the placement catheter 42 is introduced into the post-branching vessel 20 from the pre-branching vessel 21 until
10 substantially only the first flange member 15 is still positioned within the pre-branching vessel 21;

Step 3: the introducer catheter 41 is pulled back to expose the first flange member 15 of the intraluminal stent 10;
15

Step 4: the first flange member 15 moves from its radially compressed state to its radially expanded state such that it abuts with at least a portion of the wall of the pre-branching vessel 21 which surrounds the ostium of the post-branching vessel 20. It should be noted that in the example depicted, the stent
20 is made from Nitinol™. Accordingly, in its first radially compressed state, the first flange member 15 simply forms part of the cylinder (as shown in Figure 11). Being exposed to the surrounding body temperature, the flange member 15 takes on its "memorised" expanded state which is the outwardly flared structure described above. The expansion of the first flange member 15
25 anchors the stent 10 such that the remainder of the tubular body 11 cannot move any further downstream within the post-branching vessel 20;

Step 5: the placement catheter 42 and the membrane 45 are advanced downstream into the post-branching vessel 20 such that the portion of tubular
30 body previously compressed by the membrane 45 is caused or allowed to move from its radially compressed state to its radially expanded state such that it is caused to abut with at least a portion of the wall of the post-branching vessel 20;

Step 6: withdrawing the placement catheter 42 together with the
35 membrane 45 through the expanded tubular body 11. In this regard, it is

preferred that the membrane 45 is spring connected to the placement catheter such that it is biased against the placement catheter 42. This has the advantage that the membrane 45 is held against the placement catheter 42 during withdrawal of the placement catheter 42 thereby preventing snagging of
5 the membrane on the radially expanded stent 10.

To ensure that the stent 10 is appropriately positioned before the introducer catheter 41 is withdrawn, the first flange member 15 may have radio-opaque markers incorporated in its structure. Accordingly, the surgeon, would
10 be able to determine the exact positioning of the first flange member 15 within the vessel of the patient. Not until the at least first flange member 15 is positioned within the pre-branching vessel 21 at an area adjacent the opening of the post-branching vessel 20 would the introducer catheter 41 be withdrawn.

15 In a further embodiment of the invention as depicted in Figure 13a, the system has a membrane 47 which engages with at least a portion 48 of the intraluminal stent 10 and maintains said portion in its radially compressed state. As depicted, the membrane 47 engages with all of the tubular body 11 of the stent 10 apart from the first flange member 15. Accordingly, when the
20 introducer catheter 41 is withdrawn, the first flange member 15 is free to move from its radially compressed state to its radially expanded state.

In the embodiment depicted in Figures 13b and 13c, the placement catheter 42 includes a balloon member 49 positioned at least partially internal
25 the tubular body 11 of the intraluminal stent 10. Upon inflation of the balloon member 49, the tubular body 11, is forced radially outwardly which has the effect of breaking the membrane 47. With the membrane 47 broken, the at least one portion 48 of the tubular body 11 is free to move into its radially expanded state.

30

The delivery system of a further aspect of the invention is generally depicted as 100 in Figs. 15-17. The delivery system 100 is used for the delivery of an intraluminal stent 101 to a target vessel.

As depicted, the intraluminal stent 101 is movable from a first radially compressed state (see Fig. 15a) to a second radially expanded state (see Fig. 15b).

- 5 The delivery system 100 includes a catheter 102 comprising an elongate body which extends from a proximal end 104 to a distal end 105. The elongate body extends through an internal lumen of the intraluminal stent 101 such that the intraluminal stent 101 substantially surrounds a portion of the catheter 102.
- 10 The delivery system 100 further includes a compression member which holds the intraluminal stent 101 in its first radially compressed state and a release member 107 which causes release of the compression member and allows the intraluminal stent to move to its second radially expanded state.
- 15 The delivery system 100 is used to deliver a self-expanding intraluminal stent to a target site.

As shown in Figures 15a-15c, the compression member is a membrane 109 around the intraluminal stent. In this regard, the membrane 109 is made
20 from a suitably strong yet flexible material to compress the intraluminal stent and prevent the stent moving from its first radially compressed state to its second radially expanded state.

The release member 107 comprises a balloon member 108 positioned
25 along the length of the elongate body of the catheter 102. The balloon member 108 is substantially surrounded by the intraluminal stent 101 and when the balloon member 108 is inflated the intraluminal stent is forced radially outward.

The membrane 109 includes a series of perforations along its length
30 which are broken upon inflation of the balloon member 108 (as shown in Figure 15c). Fig. 15c depicts the expanded intraluminal stent 101 and the separated portions of the membrane 109. As shown, the separated portions of the membrane 109 remain attached to the stent 101 on expansion of the stent. In another embodiment, the membrane 109 is attached at its proximal end to the
35 catheter 102 such that it may be withdrawn from the target vessel with the catheter 102.

The delivery system of Figure 16 operates in a manner similar to that described above except that the compression member comprises a number of tie members or sutures 111 which hold the intraluminal stent 101 around the
5 catheter 102 and prevent the intraluminal stent 101 moving from its first compressed state to its second expanded state.

In this embodiment, the sutures 111 holding the intraluminal stent 101 to the catheter 102 have a predetermined breaking strength. Accordingly, when
10 the balloon member 108 moves from its deflated state to its inflated state, the sutures 111 break thereby allowing the intraluminal stent 101 to move to its second radially expanded state.

Another embodiment of a delivery system is depicted in Figs. 17a to 17b.
15 In this embodiment, the compression member comprises a membrane 109 around the intraluminal stent 101. The membrane has a perforation along at least a portion of its length. The release member in this embodiment is a pull suture 112 which is aligned with and/or threaded through the perforation of the membrane 109. The pull suture 112 typically extends to a location outside the
20 body or is connected to an actuator member located outside the body such that when the intraluminal stent 101 is in position at a target site, the pull suture 112 is drawn in a direction towards the proximal end of the intraluminal stent 101 such that the perforation is broken and the compressive force of the membrane 109 released from the intraluminal stent 101 which may then move to its
25 radially expanded state.

In the embodiment of the delivery system depicted in Fig. 18, the compression member is an expandable membrane 121. The membrane 121 is sealed around the stent 101 on delivery of the stent 101 into the target vessel.
30

The release member comprises a fluid that can be delivered to the sealed membrane 121 and so expand the membrane 121. The fluid is delivered into the sealed membrane 121 by the catheter 102 through apertures 122 therein.
35

The membrane 121 breaks into one or more portions 121a and 121b on undergoing a predetermined degree of expansion. In the depicted embodiment, the proximal end 123 of the portions are connected to the catheter 102 and are withdrawable from the target vessel on withdrawal of the
5 catheter 102 therefrom.

In this embodiment, the membrane 121 can contain or include one or more pharmaceutical agents. In another embodiment, one or more pharmaceutical agents can be delivered with the fluid from the catheter 102
10 and into the pocket formed by the sealed membrane 121.

In the depicted embodiment, the stent 101 is a self-expanding stent that expands in the direction depicted by arrows A on expansion of the membrane 121. It will be appreciated that in another embodiment, the stent can be a
15 passive stent that requires expansion by a secondary mechanism, such as a balloon catheter.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the
20 specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

CLAIMS:

1. An intraluminal stent comprising a tubular body extending from a proximal end to a distal end, said tubular body being capable of expanding or
5 being expanded from a radially compressed state to a radially expanded state wherein, when at least in the radially expanded state, the tubular body comprises at least a first flange member positioned at or adjacent to the proximal end of the tubular body and extending outwardly from said tubular body.
- 10 2. The intraluminal stent of claim 1 wherein said first flange member extends outwardly and away from the proximal end of the tubular body of the stent to give the tubular body a trumpet-like appearance.
- 15 3. The intraluminal stent of claim 2 wherein the first flange member is integral with the proximal end of the tubular body and extends to an outer rim.
4. The intraluminal stent of claim 3 wherein the outer rim forms a lipped portion which curves back in a general direction towards the distal end of the
20 tubular body.
5. The intraluminal stent of any one of the preceding claims further comprising a second flange member positioned at or adjacent the distal end of the tubular body.
- 25 6. The intraluminal stent of claim 5 wherein said second flange member extends outwardly and away from the distal end of the tubular body of the stent.
7. The intraluminal stent of claim 6 wherein the second flange member is
30 integral with the distal end of the tubular body and extends to an outer rim.
8. The intraluminal stent of claim 7 wherein the outer rim forms a lipped portion which curves back in a general direction towards the proximal end of the tubular body.

9. The intraluminal stent of any one of the preceding claims when made from a shape memory material including NitinolTM.
10. The intraluminal stent of any one of the preceding claims wherein the tubular body of the stent is made up of a series of cells.
11. The intraluminal stent of claim 10 wherein there are cells along the length of the tubular body, with the cells varying in size and configuration along said length of the tubular body.
12. The intraluminal stent of claim 11 wherein the first flange member is made from a series of cells which are larger and/or more elongate than the remainder of the cells of the tubular body.
13. The intraluminal stent of claim 11 or claim 12 wherein the cells of the flange member are at an angle relative to the remainder of the cells of the tubular body.
14. The intraluminal stent of any one of the preceding claims when used in the treatment of ostial stenosis including ostial stenosis of the renal and mesenteric arteries, the iliac artery and the sub-clavian artery.
15. The intraluminal stent of claim 14 wherein the first flange member is positionable within a pre-branching vessel of the ostial stenotic region and wherein said first flange member substantially engages at least a portion of the wall of the pre-branching vessel which surrounds the ostium of a post-branching vessel.
16. The intraluminal stent of claim 15 wherein the part of the tubular body of the stent not comprising the first flange member is extendable into the post-branching vessel and wherein the first flange member anchors said part of the tubular body within the post-branching vessel thereby preventing longitudinal movement of the intraluminal stent into the post-branching vessel.
17. The intraluminal stent of any one of the preceding claims wherein the tubular body of the stent further includes at least one engagement member

which is connected to or integral with a wall of the tubular body at a position located intermediate the proximal end and the distal end of the tubular body.

18. The intraluminal stent of claim 17 wherein the engagement member
5 comprises a spur or a number of spurs or other such members which extend outwardly and away from the tubular body of the stent.

19. The intraluminal stent of any one of claims 1 to 17 wherein the at least one engagement member comprises a ridge or like area or a series of ridges of
10 increased cross sectional diameter than those portions of the tubular body immediately proximal and distal each ridge.

20. The intraluminal stent of any one of the preceding claims wherein the tubular body is coated with materials to promote adhesion of cells or cell
15 growth.

21. A method of positioning the intraluminal stent of claim 1 in a vessel of a patient, the method comprising the steps of:

(i) introducing a catheter or other delivery device into a vein, artery or
20 other vessel in the body of a patient when the tubular body of the intraluminal stent is in the radially compressed state;

(ii) causing the intraluminal stent to be carried through the catheter or other delivery device to a target site of stenosis at a bifurcation between a first pre-branching vessel and a second post-branching vessel;

25 (iii) causing or allowing the tubular body of the intraluminal stent to expand such that the at least first flange member is positioned at least partially within the pre-branching vessel and the remainder of the tubular body of the stent extends into the post-branching vessel; and

(iv) withdrawing the catheter or other delivery device along with any
30 other apparatus used to introduce the intraluminal device into the vessel from the body of the patient.

22. A delivery system for the delivery of the intraluminal stent of claim 1 to a target vessel, said delivery system comprising an introducer catheter having an
35 elongate tubular body to allow the passage therethrough of a placement catheter, said placement catheter having an elongate body which extends from

a proximal end to a distal end and which carries the stent of claim 1 at a position intermediate said proximal end and said distal end, the delivery system further comprising a membrane which engages a portion of the tubular body of the intraluminal stent not comprising the at least first flange member wherein
5 said membrane acts to maintain said portion of the tubular body in its radially compressed state.

23. A method of delivering the intraluminal stent of claim 1 using the delivery system of claim 22, said method comprising the steps of:

10 (i) introducing the introducer catheter into a vein, artery or other vessel in the body of a patient wherein the tubular body of the intraluminal stent is in the radially compressed state;

(ii) causing the intraluminal stent, the placement catheter and the membrane to be carried through the introducer catheter to a target site of
15 stenosis at a bifurcation between a first pre-branching vessel and a second post-branching vessel;

(iii) introducing the distal end of the placement catheter into the post-branching vessel from the pre-branching vessel until substantially only the at least first flange member is still positioned within the pre-branching vessel;

20 (iv) withdrawing the introducer catheter to expose the at least first flange member of the intraluminal stent;

(v) causing or allowing the at least first flange member to move from its radially compressed state to its radially expanded state such that it is caused to abut with at least a portion of the wall of the pre-branching vessel which
25 surrounds the opening of the post-branching vessel;

(vi) advancing the placement catheter and the membrane further into the post-branching vessel such that the compression on the portion of the tubular body substantially surrounded by the membrane, by said membrane is released, allowing said portion of the tubular body to move from its radially
30 compressed state to its radially expanded state and into abutment with at least a portion of the wall of the post-branching vessel; and

(vii) withdrawing the placement catheter together with the membrane through the expanded tubular body.

35 24. A delivery system for the delivery of an intraluminal stent to a target vessel, said delivery system comprising an introducer catheter having an

elongate tubular body to allow the passage therethrough of a placement catheter, said placement catheter having an elongate body which extends from a proximal end to a distal end and which carries the intraluminal stent at a position intermediate said proximal end and said distal end; the delivery system
5 further comprising a membrane which engages at least a portion of the intraluminal stent such that said portion of the stent is prevented from moving from a first radially compressed state to a second radially expanded state.

25. The delivery system of claim 22 or claim 24 wherein the membrane
10 extends around the circumference of the tubular body of the intraluminal stent.

26. The delivery system of claim 25 wherein the membrane is made from a suitably strong material to act as a compressive force upon the stent thereby preventing the stent from moving to its radially expanded state.

15

27. The delivery system of claim 25 or claim 26 wherein the placement catheter includes a balloon member which is positioned at least partially within an internal lumen of the tubular body of the intraluminal stent.

20 28. The delivery system of claim 27 wherein inflation of the balloon member forces the intraluminal stent radially outwardly thereby breaking a region of the membrane.

25 29. The delivery system of any one of claims 22 and 24 to 28 wherein the membrane contains or includes a pharmaceutical agent.

30. A delivery system for the delivery of an intraluminal stent to a target vessel, said intraluminal stent being movable from a first radially compressed state to a second radially expanded state at a target site within the vessel, said
30 delivery system comprising a catheter which in turn comprises an elongate body which extends from a proximal end to a distal end wherein the elongate body extends through an internal lumen of the intraluminal stent such that said intraluminal stent substantially surrounds a portion of the catheter; the delivery system further comprising at least one compression member which holds the
35 intraluminal stent in its first radially compressed state and a release member

which causes release of the compression member and allows the intraluminal stent to move to its second radially expanded state.

31. The delivery system of claim 30 when used to deliver a self expanding
5 intraluminal stent to a target site.

32. The delivery system of claim 30 or claim 31 wherein the compression member comprises a membrane around the intraluminal stent.

10 33. The delivery system of claim 30 or claim 31 wherein the compression member includes a tie member or a series of tie members which anchor the intraluminal stent to the catheter and prevent the intraluminal stent moving from its first compressed state to its second expanded state.

15 34. The delivery system of claim 33 wherein the tie member(s) are sutures which have a pre-determined breaking strength.

35. The delivery system of claim 30 or claim 31 wherein the compression member comprises one or more of a collar, ring or spiral wrap or combinations
20 thereof around the intraluminal stent.

36. The delivery system of any one of claims 31 to 34 wherein the release member comprises a balloon member positioned along the length of the elongate body of the catheter.

25 37. The delivery system of claim 36 wherein the balloon member is substantially surrounded by the intraluminal stent.

38. The delivery system of claim 36 or claim 37 wherein movement of the
30 balloon member from a first deflated state to a second inflated state releases the compressive force of the compression member.

39. The delivery system of claim 38 wherein said membrane has at least one frangible region such that when the balloon member moves from its deflated to
35 inflated state, said at least one frangible region is broken and the intraluminal stent is allowed to move to its second radially expanded state.

40. The delivery system of claim 39 wherein the intraluminal stent is a self expanding stent.

5 41. The delivery system of claim 39 wherein said frangible region comprises one or more perforations in the body of the membrane.

42. The delivery system of claim 30 wherein the compression member is a membrane around the intraluminal stent, said membrane having at least
10 frangible region along at least a portion of its length, and said release member is a pull suture which is aligned with and/or threaded through the frangible region of the membrane.

43. The delivery system of claim 42 wherein the pull suture extends to a
15 location outside the body such that when the intraluminal stent is in position at a target site, the pull suture is movable in a direction towards the proximal end of the intraluminal stent such that the frangible region is broken and the compressive force of the membrane released from the intraluminal stent which may then move to its radially expanded state.

20 44. The delivery system of claim 30 wherein the compression member is an expandable membrane.

45. The delivery system of claim 44 wherein the membrane is sealed around
25 the stent.

46. The delivery system of claim 45 wherein the release member comprises a fluid that can be delivered to the sealed membrane and so expand the membrane.

30 47. The delivery system of claim 46 wherein the fluid is delivered into the sealed membrane by the catheter through apertures therein.

48. The delivery system of claim 47 wherein the membrane breaks into one
35 or more portions on undergoing a predetermined degree of expansion.

49. The delivery system of claim 48 wherein said one or more portions of the membrane are connected to the catheter and are withdrawable from the target vessel on withdrawal of the catheter therefrom.

5 50. The delivery system of claim 45 wherein the membrane contains or includes one or more pharmaceutical agents.

51. The delivery system of claim 46 wherein one or more pharmaceutical agents are delivered into a pocket formed by the sealed membrane.

10

52. The delivery system of claim 44 wherein the stent is a self-expanding stent that expands on expansion of the membrane.

53. The delivery system of claim 44 wherein the stent is a passive stent that
15 requires expansion by a secondary mechanism.

54. The delivery system of claim 53 wherein the secondary mechanism is a balloon catheter.




FIG. 1a
















FIG. 1b












FIG. 11




FIG. 12a




FIG. 12b




FIG. 12c




FIG. 12d




FIG. 13a




FIG. 13b




FIG. 13c




FIG. 14a




FIG. 14b




FIG. 14c




FIG. 14d




FIG. 15a




FIG. 15c





FIG. 15b






FIG. 16




FIG. 17a




FIG. 17b




FIG. 18a




FIG. 18b

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/01225

A. CLASSIFICATION OF SUBJECT MATTER												
Int. Cl. ⁷ : A61F 2/06, A61M 25/00												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols)												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DWPI IPC A61F, A61M, A61B and Keywords (stent, vascul, curv, lip) and like terms DWPI IPC A61B, A61F and Keywords (stent, catheter, introduc, film, compress) and like terms												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X	US 5064435 A (PORTER) 12 November 1991 column 6, lines 28-43, column 7, lines 25-64, Figs. 1, 5, 6	1, 2, 5, 6, 9, 10										
X	EP 0666065 A1 (MORI) 9 August 1995 column 2, lines 40-54, Fig. 2	1, 2, 5, 9, 10										
X	WO 92/19310 A1 (ADVANCED CORONARY TECHNOLOGY INC) 12 November 1992 abstract, page 8, lines 12-21, page 17, lines 9-16, Fig. 10A	1, 2, 5, 6, 9										
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 8 November 2002		Date of mailing of the international search report 20 NOV 2002										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer VINCE BAGUSAUSKAS Telephone No : (02) 6283 2110										

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/01225

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0941714 A1 (BIOCOMPATIBLES LIMITED) 15 September 1999 column 2, line 27 to column 3, line 10, Fig. 1	1, 2, 9, 10-13
X	US 5662703 A (YUREK et al) 2 September 1997 column 4, line 17 to column 5, line 40 Figs. 1, 2	24-26
X, P	WO 01/97715 A1 (SOLEM) 27 December 2001 abstract Figs. 1-4	30-32, 35-41, 44
X	US 5549635 A (SOLAR) 27 August 1996 column 6, line 13 to column 7, line 46 Figs. 4a-4c	30-32, 35-41, 44
X	EP 0732087 A1 (ADVANCED CARDIOVASCULAR SYSTEMS INC) 18 September 1996 column 5, line 24 to column 8, line 14 Figs. 1, 2	30, 32, 35, 42, 43
X	WO 97/48343 A1 (LOCALMED INC) 24 December 1997 page 14, line 23 to page 15, line 18, page 17, lines 15-31 Figs. 1-3C	30-32, 35
X	WO 01/54614 A2 (ADVANCED CARDIOVASCULAR SYSTEMS INC) 2 August 2001 page 9, lines 13-29 Fig. 1	30-32, 35
X	US 6183481 B1 (LEE et al) 6 February 2001 abstract Fig. 6	30-32, 35
X	US 5980533 A (HOLMAN) 9 November 1999 column 3, line 5 to column 4, line 3 Fig. 1	30-32, 35
X	WO 98/12988 A1 (SCIMED LIFE SYSTEMS INC) 2 April 1998 abstract Figs. 1-3	30-32, 35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/01225

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims 1-23
Intraluminal stent comprising a first flange member,
2. Claims 24-54
Intraluminal stent delivery system comprising a compression member.

As reasoned on the extra sheet:

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/01225

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

The different inventions are:

1. Claims 1-23 are directed to an intraluminal stent comprising a tubular body extending from a proximal end to a distal end, said tubular body being capable of expanding or being expanded from a radially compressed state to a radially expanded state wherein, when at least in the radially expanded state, the tubular body comprises at least a first flange member positioned at or adjacent to the proximal end of the tubular body and extending outwardly from said tubular body. It is considered that the flange member extending outwardly from the proximal end of the tubular body comprises a first "special technical feature".
2. Claims 24-54 are directed to a delivery system for the delivery of an intraluminal stent to a target vessel, said intraluminal stent being movable from a first radially compressed state to a second radially expanded state, said delivery system comprising a catheter which carries the intraluminal stent to the target vessel and a compression member which prevents the intraluminal stent from moving from a first radially compressed state to a second radially expanded state. It is considered that the compression member which prevents the intraluminal stent from moving from a first radially compressed state to a second radially expanded state comprises a second "special technical feature".

Since the abovementioned groups of claims do not share any of the technical features identified, a "technical relationship" between the inventions, as defined in PCT rule 13.2 does not exist. Accordingly the international application does not relate to one invention or to a single inventive concept, a priori.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/01225

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	5064435	CA	2086333	DE	9190098	EP	536164
		WO	92/00043				
EP	666065	US	5466242				
WO	92/19310	CA	2109312	EP	585326	US	5197978
EP	941714	AU	32676/99	WO	99/45861		
US	5662703	AU	46321/96	CA	2218072	EP	820259
		WO	96/32078				
WO	01/97715	NONE					
US	5549635	EP	819015	WO	96/31249		
EP	732087	CA	2171787	JP	08-322943	US	5647857
WO	97/48343	AU	35734/97	US	5797952		
WO	01/54614	EP	1251796				
US	6183481	WO	01/21104				
US	5980533	WO	99/63909				
WO	98/12988	AU	42366/97	EP	1006939	US	5957930
END OF ANNEX							